AIDSWEEKLY Plus; Monday, July 7, 2003
Staff Medical Writers

According to published research from Thailand, "a study of maternal complications after elective Caesarean section in HIV infected women was carried out from January 1999 to April 2001."

"The control group consisted of all the seronegative pregnant women who underwent the elective Caesarean section during the study period," noted P. Panburana and colleagues at Mahidol University.

"The study group was divided into two subgroups," they said. "Subgroup 1 patients were given 600 mg zidovudine (ZDV) orally and 300 mg lamivudine (3TC) daily from 34 to 38 weeks gestation. Subgroup 2 patients were given 600 mg ZDV orally daily from 34 to 38 weeks' gestation and 150 mg nevirapine orally on the morning of the Caesarean section day."

"In both groups, the elective Caesarean section was carried out at 38 weeks' gestation and ZDV syrup (2 mg/kg) was given orally to the newborn immediately in the operating theater and then every six hours for four weeks," according to the report.

"No statistically significant differences in maternal complications were found between the HIV-infected and non-HIV infected women," the researchers concluded.

Panburana and coauthors published their study in the Australian and New Zealand Journal of Obstetrics and Gynaecology (Maternal complications after Caesarean section in HIV-infected pregnant women. Aust N Z J Obstet Gynaecol, 2003;43(2):160-163).

For additional information, contact P. Panburana, Mahidol University, Ramathibodi Hospital, Faculty of Medicine, Department of Obstetrics and Gynecology, Rama 6 Rd., Bangkok 10400, Thailand.

The publisher's contact information for the Australian & New Zealand Journal of Obstetrics & Gynaecology is: Royal Australian N Z College Obstetricians & Gynecologists, 254-260 Albert St., East Melbourne, Vic 3002, Australia.

The information in this article comes under the major subject areas of AIDS and HIV, Obstetric and Women's Health.

This article was prepared by AIDS Weekly editors from staff and other reports.

030707
AW030703

Copyright © 2003 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.